Merck Message Board - Msg: 24451950

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck

MRK 98.07

-2.2%

12:46 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Carey Thompson who wrote (1542)	3/30/2008 2:47:18 AM
From: Carey Thompson	Read Replies (1) of 1580

Update on MK 518. I received my Annual Report from Merck this week, and to my surprise MK 518 passed muster or FDA Phase III trials. MK 518 is now a drug named Isentress. Please read/de-cipher the following features from the Merck 2007 Annual Report. HIV is stopped. Too bad Merck cannot communicate this to the average person. merck.com merck.com NOTE:For 20 years, Scott Gilmore’s blood tests have consistently revealed detectable levels of the HIV virus. Not anymore. Since adding Isentress to his other antiretroviral medicines, his viral load has fallen – for the first time ever – to undetectable levels. Although not everyone responds so dramatically, Scott’s experience shows why Isentress is bringing hope to so many patients and their physicians.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next